drugset / Trial / NCT06703073
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
Phase 2
Recruiting
600 enrolled
PPD Development, LP
Biomedical Advanced Research and Development Authority · collabEdesa Biotech Inc. · collabGenentech, Inc. · collabInflaRx GmbH · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Participants will be randomized to receive either a placebo or one of the active treatments. This record describes the default procedures and analyses for all cohorts. Each specific cohort may have additional eligibility requirements, safety and efficacy procedures, or endpoints, which will be described in the corresponding intervention-specific records on clinicaltrials.gov listed below in the detailed description.
Timeline
- Start
- 2025-06-10
- Primary completion
- 2028-07
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 500 mg | Intravenous |
| Subject | paridiprubart | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | vilobelimab | Monoclonal antibody | 800 mg | Intravenous |